ArticleEuropean journal of case reports in internal medicine2024
Movement Disorders that Occurred as Late Manifestations of Alzheimer's Disease Controlled by a Low dose of Carbamazepine.
Article in European journal of case reports in internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-regional transcriptomic analysis reveals early nociceptive and neuroinflammatory alterations in APP/PS1 mice.Frontiers in immunology · 2026Article
- The Endothelial Cell-Related GenesBrain sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: According to the World Health Organization, 44 million people worldwide suffer from Alzheimer's disease. Abnormal movements are atypical symptoms of Alzheimer's disease. Case description: An 87-year-old woman, followed for Alzheimer's disease, experienced abnormal movements. The episodes lasted 30 minutes, were involuntary, uncontrollable, anarchic, predominantly in the upper limbs, and without loss of consciousness or bladder control. An electroencephalogram ruled out atypical epilepsy. Pharmacovigilance investigation ruled out a drug-related cause. Magnetic resonance imaging revealed abnormalities suggestive of Alzheimer's disease, with no other evidence to explain the abnormal movements. Apart from the presence of Alzheimer's disease biomarkers, cerebrospinal fluid analysis found no abnormality. Dopamine transporter scan rule out an atypical parkinsonian syndrome. Finally, abnormal movements associated with Alzheimer's disease were suspected. Abnormal movements disappeared within 72 hours on low-dose carbamazepine. Conclusion: This case is educational both because of the clinical presentation and the management of symptoms. LEARNING POINTS: The number of people suffering from Alzheimer's disease, the leading cause of major neurocognitive disorders, is expected to reach around 78 million in 2030 and 139 million in 2050.The course of Alzheimer's disease may be punctuated by atypical symptoms, such as abnormal movements.In patients on carbamazepine, we observed a dramatic improvement in abnormal movements associated with Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.